EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria

Tingting Zhang, Jian Du, Lingling Dong, Fen Wang, Liping Zhao, Junnan Jia, Congli Wang, Mengli Cheng, Xia Yu, Hairong Huang iD

Microbiology Spectrum · 14.02.2023 · 11 (1)

DOI: 10.1128/spectrum.03238-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 14.02.2023. Verfasst von Tingting Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medica…. Hauptthemen laut MEDLINE: Mycobacterium, Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Fundation of China, Beijing Hospitals Authority Youth Programme, Beijing Public Health Experts Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global rise in antibiotic-resistant nontuberculous mycobacteria has prompted the urgent need for new antimicrobials, especially oral antibiotics. Currently, adverse effects have limited the use of tetracycline-class antibiotics, particularly tigecycline (TGC), in the treatment of rapidly growing mycobacteria (RGM).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycobacteriumMycobacterium abscessusMycobacterium Infections, NontuberculousHumansTigecyclineTetracyclineTetracyclinesAnti-Bacterial AgentsMicrobial Sensitivity TestsNontuberculous Mycobacteria

Stichwörter der Autor:innen

antimicrobial activityeravacyclineomadacyclinerapidly growing mycobacteriasarecyclinetigecycline

Substanzen

omadacyclineTigecyclinesarecyclineeravacyclineTetracyclineTetracyclinesAnti-Bacterial Agents

Autor:innen und Institutionen

  • National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beiji…

ORCID-Profile: Hairong Huang

Förderung

  • National Natural Science Fundation of China
  • Beijing Hospitals Authority Youth Programme
  • Beijing Public Health Experts Project
  • Capital's Funds for Health Improvement and Research

Zitieren

APA

Zhang, T., Du, J., Dong, L., Wang, F., Zhao, L., Jia, J., Wang, C., Cheng, M., Yu, X., & Huang, H. (2023). In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. Microbiology Spectrum, 11(1). https://doi.org/10.1128/spectrum.03238-22

Vancouver

Zhang T, Du J, Dong L, Wang F, Zhao L, Jia J, et al. In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. Microbiology Spectrum. 2023;11(1). doi:10.1128/spectrum.03238-22

BibTeX
@article{Zhang2023,
  author = {Zhang, Tingting and Du, Jian and Dong, Lingling and Wang, Fen and Zhao, Liping and Jia, Junnan and Wang, Congli and Cheng, Mengli and Yu, Xia and Huang, Hairong},
  title = {In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {1},
  doi = {10.1128/spectrum.03238-22}
}
Kostenlos starten →